Bruce Booth Sells 169,260 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Bruce Booth sold 169,260 shares of the stock in a transaction that occurred on Thursday, October 16th. The stock was sold at an average price of $32.35, for a total transaction of $5,475,561.00. Following the completion of the transaction, the director owned 722,301 shares in the company, valued at $23,366,437.35. The trade was a 18.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Bruce Booth also recently made the following trade(s):

• On Tuesday, October 21st, Bruce Booth sold 88,878 shares of Sionna Therapeutics stock. The stock was sold at an average price of $34.22, for a total transaction of $3,041,405.16.
• On Monday, October 20th, Bruce Booth sold 55,985 shares of Sionna Therapeutics stock. The stock was sold at an average price of $32.09, for a total transaction of $1,796,558.65.
• On Friday, October 17th, Bruce Booth sold 61,124 shares of Sionna Therapeutics stock. The stock was sold at an average price of $32.37, for a total transaction of $1,978,583.88.
• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.61, for a total transaction of $3,546,352.16.
• On Tuesday, October 14th, Bruce Booth sold 606 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total transaction of $18,149.70.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.38, for a total transaction of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.98, for a total transaction of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total transaction of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total transaction of $5,990.00.

Sionna Therapeutics Price Performance

Shares of NASDAQ SION opened at $42.50 on Wednesday. The firm has a fifty day moving average price of $26.19 and a 200-day moving average price of $18.93. Sionna Therapeutics, Inc. has a 1 year low of $7.26 and a 1 year high of $43.20.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.27.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SION shares. Raymond James Financial started coverage on shares of Sionna Therapeutics in a research note on Tuesday, September 2nd. They set a “strong-buy” rating and a $45.00 target price for the company. Jones Trading started coverage on shares of Sionna Therapeutics in a research note on Monday, September 8th. They set a “buy” rating and a $46.00 target price for the company. Royal Bank Of Canada started coverage on shares of Sionna Therapeutics in a research note on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 target price for the company. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sionna Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $38.00.

Hedge Funds Weigh In On Sionna Therapeutics

Several institutional investors have recently bought and sold shares of SION. RA Capital Management L.P. bought a new position in Sionna Therapeutics during the first quarter valued at $109,258,000. TPG GP A LLC bought a new position in Sionna Therapeutics during the first quarter valued at $69,925,000. Atlas Venture Life Science Advisors LLC bought a new stake in shares of Sionna Therapeutics in the 1st quarter worth about $38,639,000. Braidwell LP bought a new stake in shares of Sionna Therapeutics in the 2nd quarter worth about $18,770,000. Finally, Jennison Associates LLC bought a new stake in shares of Sionna Therapeutics in the 1st quarter worth about $8,995,000.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.